E Fund Management Co. Ltd. cut its holdings in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 67.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,458 shares of the company’s stock after selling 28,251 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Altimmune were worth $89,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in ALT. North Star Investment Management Corp. purchased a new position in shares of Altimmune during the first quarter valued at about $31,000. CANADA LIFE ASSURANCE Co purchased a new position in Altimmune during the 1st quarter valued at approximately $44,000. Russell Investments Group Ltd. increased its stake in Altimmune by 1,150.9% in the 4th quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company’s stock worth $48,000 after acquiring an additional 3,959 shares during the last quarter. TFO Wealth Partners LLC purchased a new stake in shares of Altimmune during the 1st quarter worth approximately $51,000. Finally, Horizon Wealth Management LLC purchased a new stake in shares of Altimmune during the 2nd quarter worth approximately $66,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.
Altimmune Trading Up 1.9 %
Shares of NASDAQ:ALT opened at $7.57 on Friday. Altimmune, Inc. has a 12 month low of $2.09 and a 12 month high of $14.84. The company has a market capitalization of $536.73 million, a price-to-earnings ratio of -4.75 and a beta of 0.08. The firm’s 50-day moving average is $6.71 and its 200 day moving average is $7.46.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on ALT shares. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Altimmune in a report on Thursday, August 22nd. Evercore ISI upgraded shares of Altimmune to a “strong-buy” rating in a report on Friday, August 9th. B. Riley reaffirmed a “buy” rating and issued a $20.00 price target on shares of Altimmune in a report on Monday, August 12th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $25.00 price target on shares of Altimmune in a research report on Friday, June 21st. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.80.
Check Out Our Latest Stock Analysis on Altimmune
Insider Transactions at Altimmune
In related news, Director David Drutz sold 16,011 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $6.90, for a total value of $110,475.90. Following the transaction, the director now owns 41,958 shares of the company’s stock, valued at approximately $289,510.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.10% of the company’s stock.
Altimmune Profile
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
See Also
- Five stocks we like better than Altimmune
- How is Compound Interest Calculated?
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- 3 Fintech Stocks With Good 2021 Prospects
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Want to see what other hedge funds are holding ALT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Altimmune, Inc. (NASDAQ:ALT – Free Report).
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.